Innovative Treatment Adoption Vertos Medical's proprietary Mild® procedure offers a minimally invasive, outpatient solution for lumbar spinal stenosis that has demonstrated strong safety and durability, positioning it as an attractive alternative for hospitals and clinics seeking to enhance their pain management offerings.

Strong Growth Momentum Ranked 370 on the Deloitte Technology Fast 500 and recognized as a Technology Fast 500 award winner for 2022, Vertos has demonstrated significant growth potential, making it a promising candidate for strategic partnerships and investments to support further expansion.

Strategic Leadership Recent leadership appointments of a Chief Commercial Officer and a Chief Technology Officer, along with a $130 million funding round, signal a focus on scaling sales, expanding technological capabilities, and capturing greater market share in the minimally invasive spinal treatments space.

Market Coverage & Reimbursement The Mild procedure is nationally covered by Medicare and has been performed on thousands of patients, indicating a positive reimbursement environment and existing healthcare provider adoption that sales teams can leverage to promote further clinical adoption.

Expanding Customer Base With a focused product for a high-demand condition and increasing visibility in the healthcare market, Vertos presents opportunities to partner with hospitals, outpatient clinics, and specialists looking for innovative, effective options for lumbar stenosis treatment to grow their patient offerings.